Roivant and Priovant report brepocitinib met the primary endpoint in Phase III uveitis trials. Read the latest results and ...
Kyverna reports one-year Phase II data for miv-cel in stiff person syndrome and plans a rolling BLA filing. Read the full ...
Muna Therapeutics' oral TREM2 modulator MNA-001 showed no serious adverse events in Phase I. Read how the Phase II ...
Olorofim meets its non-inferiority goal against AmBisome in the Phase III OASIS trial for invasive aspergillosis. Read full ...
City Therapeutics (Nasdaq: CTY), a clinical-stage RNAi company, closed its upsized IPO raising $230M at $18 per share. Read ...
Rapport Therapeutics' RAP-219 met primary and secondary endpoints in a Phase II bipolar mania trial, cutting YMRS scores. See results and Phase III plans.
Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...
Hologic signs deal to acquire Barcelona-based Reveal Genomics, expanding breast cancer diagnostics to complement its BCI test. Read the full deal details.
FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.
Lilly's Omvoh met its Phase III primary endpoint in pediatric ulcerative colitis, with 50% of responders in remission at Week ...
Gilead's oral α4β7 integrin inhibitor emvistegrast met the primary endpoint in Phase II SWIFT study for ulcerative colitis.
FDA unveils Rare Disease Framework Initiative to overhaul how rare-condition drugs are developed and reviewed. See how it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results